Dual phosphodiesterase 3 and 4 inhibitors: the new kind of COPD blocker? - Vienna 2024

Implementing new strategies and treatments in asthma and chronic obstructive pulmonary disease

Chair(s): Emer Kelly, Augusta Beech, Stylianos Loukides

Session type: Symposium

Dual phosphodiesterase 3 and 4 inhibitors: the new kind of COPD blocker?

Paola Rogliani

EVENTS HOME

Replay
Slides

Previous presentation

Next presentation

Session content

Anti-inflammatory reliever in clinical practice in asthma: how to implement in the background of GINA?

Anneke Ten Brinke

Replay

Slides

Biological therapy in asthma: how to deal with the many options available

Florence Schleich

Replay

Slides

Dual phosphodiesterase 3 and 4 inhibitors: the new kind of COPD blocker?

Paola Rogliani

Replay

Slides

Biologics in COPD a recipe for failure or success?

Christopher E. Brightling

Replay

Slides

Discussion and Q&A

Replay

Session aims

To update European Respiratory Society members on the novel therapies developed in recent years for airway diseases, asthma and chronic obstructive pulmonary disease; to explore the current status and future of innovative and well-established therapies that can be accessed to help patients.

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}